The estimated Net Worth of John Mcgrath is at least $5.55 million dollars as of 19 March 2018. John Mcgrath owns over 6,000 units of Atara Biotherapeutics Inc stock worth over $737,612 and over the last 10 years John sold ATRA stock worth over $4,813,780.
John has made over 26 trades of the Atara Biotherapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently John sold 6,000 units of ATRA stock worth $242,460 on 19 March 2018.
The largest trade John's ever made was exercising 65,357 units of Atara Biotherapeutics Inc stock on 15 May 2015 worth over $543,117. On average, John trades about 10,126 units every 30 days since 2014. As of 19 March 2018 John still owns at least 88,762 units of Atara Biotherapeutics Inc stock.
You can see the complete history of John Mcgrath stock trades at the bottom of the page.
John's mailing address filed with the SEC is 611 Gateway Blvd #900, South San Francisco, CA 94080, USA.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier et Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: